14.80 USD
▲+0.30+2.28%
盘后 14.49 +0.10%
2026-08-03
市值
$1.90B
市盈率
—
EPS
-0.07
股息率
—
52 周区间
12.66 – 21.50
成交量
119.31K
Beta
0.80
目标价
35.00
52W 低 12.6652W 高 21.50
价格走势
公司简介
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...